Specific polyclonal F(ab')2 neutralize a large panel of highly pathogenic avian influenza A viruses (H5N1) and control infection in mice.

abstract：AIMS:A therapeutic vaccine based on monocyte-derived dendritic cells (MDDCs) has been shown to represent a promising strategy for the treatment of cancer and viral infections. Here, we characterized the MDDCs used as an immunogen in a clinical trial for an anti-HIV-1 therapeutic vaccine. PATIENTS & METHODS:Monocytes o...

journal_title：Immunotherapy

authors： da Silva LT,da Silva WC,de Almeida A,da Silva Reis D,Santillo BT,Rigato PO,da Silva Duarte AJ,Oshiro TM

更新日期：2018-08-01 00:00:00

abstract：:John L Stanford speaks to Hannah Wilson, Assistant Commissioning Editor John L Stanford is Chief Scientific Officer at BioEos Ltd (Kent, UK). Dr Stanford began his career as a senior lecturer and then reader in microbiology at Middlesex Hospital Medical School (London, UK), then University College London Medical Schoo...

journal_title：Immunotherapy

authors： Stanford JL

更新日期：2013-05-01 00:00:00

abstract：:Background: Progress in immunotherapy (IT) has shifted treatment paradigms for multiple malignancies. In March 2019, the combination of nab-paclitaxel and atezolizumab was approved by the US FDA for patients with PD-L1 positive metastatic triple-negative breast cancer based on positive results of the Impassion130 tria...

journal_title：Immunotherapy

authors： Philipovskiy A,Chambers K,Konstantinidis I,McCallum R,Corral J,Gaur S

更新日期：2020-12-01 00:00:00

abstract：:Alemtuzumab (Campath®, Genzyme Corporation, MA, USA) is a potent monoclonal antilymphocyte, anti-CD52 antibody. Since the 1980s, alemtuzumab has been used extensively in organ transplantation as an induction agent - also with the aim of avoiding or reducing maintenance immunosuppression. We herein review the literatur...

journal_title：Immunotherapy

authors： Weissenbacher A,Boesmueller C,Brandacher G,Oellinger R,Pratschke J,Schneeberger S

更新日期：2010-11-01 00:00:00

abstract：:Aim: To assess the safety and effectiveness of an allergen immunotherapy (AIT) with a microcrystalline tyrosine-associated mite allergoid in real-world patients with allergic rhinitis (AR). Materials & methods: Retrospective, multicenter study assessing the safety of AIT in patients aged 5 to 65 years with AR, with or...

journal_title：Immunotherapy

authors： Sala-Cunill A,Pérez-Formoso JL,Torán-Barona C,Almeida-Sánchez ZM,Álvarez-Fernández JA,García-Núñez I,Linana-Santafé JJ,Martínez-Tadeo JA,Boronat-Barado A,Justicia JL

更新日期：2020-09-01 00:00:00

abstract：:Evaluation of: Davila ML, Riviere I, Wang X et al. Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci. Transl. Med. 6(224), 224ra25 (2014). Recently, chimeric antigen receptor (CAR) T-cell immunotherapy has entered clinical trials in patients with relapsed or refr...

journal_title：Immunotherapy

authors： Patel JM,Dale GA,Vartabedian VF,Dey P,Selvaraj P

更新日期：2014-01-01 00:00:00

abstract：:The complex homeostasis of tissues is coordinated by the cytokine network and imbalances in this network may result in chronic immune disorders. Key specific cytokines, such as TNF-alpha, IFN-alpha, IL-4 or VEGF have been demonstrated to be overproduced or abnormally released in the microenvironment of pathologic tiss...

journal_title：Immunotherapy

authors： Bizzini B,Drouet B,Zagury D,Abitbol M,Burny A,Boissier MC

更新日期：2010-05-01 00:00:00

abstract：:Although vaccination significantly reduces influenza severity, seasonal human influenza epidemics still cause more than 250,000 deaths annually. Vaccine efficacy is limited in high-risk populations such as infants, the elderly and immunosuppressed individuals. In the event of an influenza pandemic (such as the 2009 H1...

journal_title：Immunotherapy

authors： Ye J,Shao H,Perez DR

更新日期：2012-02-01 00:00:00

abstract：:Waldenström macroglobulinemia (WM) is a lymphoproliferative lymphoma that is characterized by monoclonal immunoglobulin M (IgM) protein and bone marrow infiltration. Its incidence is rare and rarer still is its ability to transform to a B-cell lymphoma, particularly the aggressive diffuse large B-cell lymphoma, which ...

journal_title：Immunotherapy

authors： Okolo ON,Johnson AC,Yun S,Arnold SJ,Anwer F

更新日期：2017-08-01 00:00:00

abstract：:Over the last few years, extensive research has improved our understanding of tumor immunology and has enabled the development of novel treatments. The state of the art of immunotherapy in various types of malignancies was exhaustively discussed in the 'Immunotherapy Bridge' meeting, which was held in Naples on 4-5 De...

journal_title：Immunotherapy

authors： Ascierto PA,Garbe C

更新日期：2020-02-01 00:00:00

abstract：:Evaluation of: Savoldo B, Ramos CA, Liu E et al. CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients. J. Clin. Invest. 121(5), 1822-1826 (2011). Chimeric antigen receptor (CAR)-T cells are promising antitumor immunotherapies. However, there are limit...

journal_title：Immunotherapy

authors： Gandhi M,Jones K

更新日期：2011-12-01 00:00:00

abstract：:Immunotherapy strategies for cancer are focused on inducing effective and specific cytotoxic responses mediated by CD8 T cells. On the other hand, immunosuppressive mechanisms induced by the tumor, such as the generation of tumor-specific CD4(+)CD25(+)FoxP3(+) Tregs, conspire against the efficacy of immunotherapies. I...

journal_title：Immunotherapy

authors： Muccioli M,Longstaff C,Benencia F

更新日期：2012-05-01 00:00:00

abstract：:The rapid emergence of multidrug-resistant pathogens, especially Gram-negative bacteria and mycobacteria, represents one of the major medical challenges of the 21st century. The gradual loss of effective classical antibiotics for many bacterial pathogens, combined with an increasing population density and mobility, ur...

journal_title：Immunotherapy

authors： Helbig ET,Opitz B,Sander LE

更新日期：2013-04-01 00:00:00

abstract：:Sarcoidosis is a systemic disease with an incidence of 1 to 40 per 100 000 persons per year. It predominantly affects people in the age of 20 to 40 years old. Disease course varies from mild self-limiting to chronic debilitating and life-threatening disease. Since the cause of sarcoidosis is unknown, curative therapy ...

journal_title：Immunotherapy

authors： Crommelin HA,Vorselaars AD,van Moorsel CH,Korenromp IH,Deneer VH,Grutters JC

更新日期：2014-01-01 00:00:00

abstract：:Over the last two decades, anti-CD20 monoclonal antibody (mAb) therapy has improved patient outcome in B-cell malignancies, and confirmed CD20 as an important target in chronic lymphocytic leukemia (CLL). Until recently, the gold standard was based on the utilization of rituximab combined with chemotherapy (fludarabin...

journal_title：Immunotherapy

authors： Bagacean C,Zdrenghea M,Tempescul A,Cristea V,Renaudineau Y

更新日期：2016-05-01 00:00:00

abstract：:Although treatment options for castration-resistant prostate cancer (CRPC) have increased over the last decade, there remains a need for strategies that can provide durable disease control and long-term benefit. Recently, immunotherapy has emerged as a viable and attractive strategy for the treatment of CRPC. To date,...

journal_title：Immunotherapy

authors： Noguchi M,Koga N,Moriya F,Itoh K

更新日期：2016-01-01 00:00:00

abstract：:Aim: Autologous hematopoietic stem cell transplantation (ASCT) is the standard-of-care curative treatment for relapsed or refractory diffuse large B-cell lymphoma (RR-DLBCL), but the relapse rate is usually high. Materials & methods: In this study, we treated 14 RR-DLBCL patients by combining ASCT and anti-CD19 chimer...

journal_title：Immunotherapy

authors： Wang T,Gao L,Wang Y,Zhu W,Xu L,Wang Y,Yue W,Tang G,Chen L,Chen J,Zhang W,Yu X,Feng D,Yang J

更新日期：2020-09-01 00:00:00

abstract：:Breast cancer cells frequently express tumor-associated antigens that can elicit immune responses to eradicate cancer. Cancer-testis antigens (CTAs) are a group of tumor-associated antigens that might serve as ideal targets for cancer immunotherapy because of their cancer-restricted expression and robust immunogenicit...

journal_title：Immunotherapy

authors： Mahmoud AM

更新日期：2018-07-01 00:00:00

abstract：:In the last 10 years, cancer stem cells have interested the scientific community because this small tumorigenic population is also associated with tumor progression in human patients and specific targeting of cancer stem cells could be a strategy to eradicate cancers currently resistant to conventional therapy. Clinic...

journal_title：Immunotherapy

authors： Iovino F,Meraviglia S,Spina M,Orlando V,Saladino V,Dieli F,Stassi G,Todaro M

更新日期：2011-01-01 00:00:00

abstract：:Mesenchymal stem cells (MSCs) show considerable promise as a cellular immunotherapy for the treatment of a number of autoimmune and inflammatory disorders. However, the precise physiologically and therapeutically relevant mechanism(s) by which MSCs mediate immune modulation remains elusive. Dental pulp stem cells are ...

journal_title：Immunotherapy

authors： Laing AG,Riffo-Vasquez Y,Sharif-Paghaleh E,Lombardi G,Sharpe PT

更新日期：2018-03-01 00:00:00

abstract：:Bacillus Calmette-Guérin and other mycobacterial vaccines are important therapeutic methods in a series of chronic inflammatory disorders characterized by Th1/Th2 imbalance in which Th2 type cells and cytokines often increase. However, few studies have investigated whether it can reduce or prevent the symptoms and att...

journal_title：Immunotherapy

authors： Ming M,Li C,Luo Z,Lv S

更新日期：2013-02-01 00:00:00

abstract：:Taking advantage of the cellular immune system is the mainstay of the adoptive cell therapy, to induce recognition and destruction of cancer cells. The impressive demonstration of this principle is chimeric antigen receptor-modified T (CAR-T)-cell therapy, which had a major impact on treating relapsed and refractory h...

journal_title：Immunotherapy

authors： El-Khazragy N,Ghozy S,Emad P,Mourad M,Razza D,Farouk YK,Mohamed NA,Ahmed MK,Youssef T,Bahnasawy YM,Elmasery S

更新日期：2020-12-01 00:00:00

abstract：:Bortezomib is an inhibitor of the ubiquitin-proteasome proteolytic pathway responsible for intracellular protein turnover. Cellular proteins controlled by this pathway represent a diverse group of potential therapeutic targets, particularly in cancer cells, which exploit this proteasomal pathway to promote their growt...

journal_title：Immunotherapy

authors： Pellom ST Jr,Dudimah DF,Thounaojam MC,Sayers TJ,Shanker A

更新日期：2015-01-01 00:00:00

abstract：AIM:We developed a novel approach to efficiently deliver autologous tumor antigens to the cytoplasm of dendritic cells (DC) using yeast cell wall particles (YCWP). MATERIALS AND METHODS:Loading of YCWP, leakage of protein from loaded YCWP and cytoplasmic delivery of YCWP content was assessed using fluorescent-tagged e...

journal_title：Immunotherapy

authors： Hardin MO,Vreeland TJ,Clifton GT,Hale DF,Herbert GS,Greene JM,Jackson DO,Berry JE,Nichols P,Yin S,Yu X,Wagner TE,Peoples GE

更新日期：2018-04-01 00:00:00

abstract：:Food allergy is a worldwide issue, with an estimated prevalence of 2-10%. An effective treatment is not available for people affected and the only management is the avoidance of the allergen. Oral immunotherapy and sublingual immunotherapy have been tested by several authors, in particular for milk, egg and peanuts al...

journal_title：Immunotherapy

authors： Praticò AD,Leonardi S

更新日期：2015-01-01 00:00:00

abstract：AIM:Previous studies showed that some patients after the treatment of anti-programmed cell death protein-1 (anti-PD-1) antibodies experienced immune-related diarrhea. In this study, we aim to explore the association between intestinal microbiota and immune-related diarrhea. METHODS:We obtained the fecal samples of 26 ...

journal_title：Immunotherapy

authors： Liu T,Xiong Q,Li L,Hu Y

更新日期：2019-04-01 00:00:00

abstract：:Myeloid-derived suppressor cells (MDSCs) are immature myeloid cells that infiltrate human and experimental tumors and strongly inhibit anticancer immune response directly or by inducing regulatory T-lymphocyte activity. Consequently, MDSCs are important actors of cancer-induced immune tolerance and a major obstacle to...

journal_title：Immunotherapy

authors： Martin F,Apetoh L,Ghiringhelli F

更新日期：2012-01-01 00:00:00

abstract：:The dysfunctional immune response that characterizes systemic lupus erythematosus (SLE) associates with an unbalanced production of soluble mediators that are crucial in promoting and sustaining chronic inflammation. The successful use of biologics in several autoimmune diseases has led to studies in SLE aimed at cont...

journal_title：Immunotherapy

authors： La Cava A

更新日期：2010-07-01 00:00:00

abstract：:Evaluation of: Boudousq V, Ricaud S, Garambois V et al.: Brief intraperitoneal radioimmunotherapy of small peritoneal carcinomatosis using high activities of noninternalizing (125)I-labeled monoclonal antibodies. J. Nucl. Med. 51, 1748-1755 (2010). Mesothelioma, pseudomyxoma peritonei, ovarian and colon cancers, and s...

journal_title：Immunotherapy

authors： Baranowska-Kortylewicz J

更新日期：2011-04-01 00:00:00

abstract：:Developing effective vaccines against Neisseria meningitidis serogroup B has been challenging for several reasons, including the fact that the capsular polysaccharide of N. meningitidis serogroup B is a poor antigen. Therefore, studies have focused on developing vaccines that target capsular protein meningococcal anti...

journal_title：Immunotherapy

authors： Esposito S,Castellazzi L,Bosco A,Musio A,Stoddard J

更新日期：2014-01-01 00:00:00